Abstract
Mental health (MH) disorders are more prevalent among persons living with HIV compared to the general population, and may contribute to suboptimal adherence to antiretroviral therapy (ART). Tenofovir-diphosphate (TFV-DP), the phosphorylated anabolite of tenofovir (TFV), is a biomarker with a 17-day half-life in red blood cells. TFV-DP can be measured in dried blood spots (DBS) using liquid chromatography/tandem mass spectrometry (LC-MS/MS) to assess adherence and cumulative drug exposure to tenofovir disoproxil fumarate (TDF)-based ART. From a larger clinical cohort (N = 807), TFV-DP concentrations and a paired HIV viral load were available from 521 participants at their enrollment visit. We used multivariable linear regression to evaluate the association between TFV-DP in DBS and engagement in MH care. After adjusting for clinical covariates, participants with MH disorders who were engaged in MH care had 40% higher TFV-DP compared to participants with MH disorders who were not engaged in MH care (p < 0.001), and similar TFV-DP to participants without MH disorders (p = 0.219). Further research is needed to identify the mechanism(s) for these findings, with the goal of optimizing engagement and retention in MH care strategies to improve ART adherence and clinical outcomes in PLWH with MH disorders.
Resumen
Las enfermedades mentales (EMs) son más frecuentes en personas que viven con VIH (PVIH), y pueden reducir la adherencia a la terapia antirretroviral (TARV). El difosfato de tenofovir (DF-TFV), el anabolito activo del tenofovir (TFV), tiene una vida media de 17 días en los eritrocitos y es cuantificable en gotas de sangre desecada (GSD) mediante cromatografía liquida y espectrometría de masa. El DF-TFV sirve come medida de adherencia y exposición acumulativa a la TARV basada en el fumarato de tenofovir disoproxil (TDF). En este estudio analizamos las concentraciones de DF-TFV en 521 PVIH derivadas de una cohorte clínica de 807 PVIH tratadas con TDF, con el objetivo de identificar si existe alguna asociación entre el DF-TFV y el cuidado activo de una EM en pacientes con este diagnóstico. Usando regresión lineal múltiple ajustada, en este análisis encontramos una reducción del 40% en las concentraciones de DF-TFV en las PVIH recibiendo tratamiento de una EM en comparación con las PVIH con un diagnóstico de EM sin recibir tratamiento activo (p<0.001), pero concentraciones similares a las de PVIH sin diagnóstico de EM (p=0.219). Las causas de estas diferencias deben ser investigadas en estudios adicionales con el fin de optimizar el tratamiento activo de las EMs y mejorar la adherencia a la TARV en PVIH con EMs.
Similar content being viewed by others
References
Springer SA, Dushaj A, Azar MM. The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review. AIDS Behav. 2012;16(8):2119–43.
Saag LA, Tamhane AR, Batey DS, Mugavero MJ, Eaton EF. Mental health service utilization is associated with retention in care among persons living with HIV at a university-affiliated HIV clinic. AIDS Res Therapy. 2018;15(1):1.
Do AN, Rosenberg ES, Sullivan PS, et al. Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveillance system. PLoS ONE. 2014;9(3):e92842.
Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34(8):1115–21.
Pence BW, Mills JC, Bengtson AM, et al. Association of increased chronicity of depression with HIV appointment attendance, treatment failure, and mortality among HIV-infected adults in the United States. JAMA Psychiatry. 2018;75(4):379–85.
Pence BW, Miller WC, Gaynes BN, Eron JJ Jr. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44(2):159–66.
Rooks-Peck CR, Adegbite AH, Wichser ME, et al. Mental health and retention in HIV care: a systematic review and meta-analysis. Health Psychol. 2018;37(6):574–85.
Grau LE, Griffiths-Kundishora A, Heimer R, et al. Barriers and facilitators of the HIV care continuum in Southern New England for people with drug or alcohol use and living with HIV/AIDS: perspectives of HIV surveillance experts and service providers. Addict Sci Clin Pract. 2017;12(1):24.
Kalichman SC, Pellowski J, Kegler C, Cherry C, Kalichman MO. Medication adherence in people dually treated for HIV infection and mental health conditions: test of the medications beliefs framework. J Behav Med. 2015;38(4):632–41.
Cholera R, Pence BW, Bengtson AM, et al. Mind the gap: gaps in antidepressant treatment, treatment adjustments, and outcomes among patients in routine HIV care in a multisite U.S. Clinical Cohort. PLoS ONE. 2017;12(1):0166435.
Remien RH. Addressing mental health: a crucial component to ending the HIV epidemic. In: Conference on retroviruses and opportunistic infections, Boston; 2018.
Tao J, Qian HZ, Kipp AM, et al. Effects of depression and anxiety on antiretroviral therapy adherence among newly diagnosed HIV-infected Chinese MSM. AIDS (London, England). 2017;31(3):401–6.
Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114(7):573–80.
Castillo-Mancilla JR, Haberer JE. Adherence measurements in HIV: new advancements in pharmacologic methods and real-time monitoring. Curr nt HIV/AIDS Rep. 2018;15(1):49–59.
Nieuwkerk PT, de Boer-van der Kolk IM, Prins JM, Locadia M, Sprangers MA. Self-reported adherence is more predictive of virological treatment response among patients with a lower tendency towards socially desirable responding. Antiviral Therapy. 2010;15(6):913–6.
Koenig HC, Mounzer K, Daughtridge GW, et al. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. HIV Med. 2017;18(6):412–8.
Haberer JE, Sabin L, Amico KR, et al. Improving antiretroviral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendations. J Int AIDS Soc. 2017;20(1):21371.
Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29(2):384–90.
Zheng JH, Rower C, McAllister K, et al. Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal. 2016;122:16–20.
Castillo-Mancilla JR, Searls K, Caraway P, et al. Short communication: tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women. AIDS Res Hum Retroviruses. 2015;31(4):428–32.
Anderson PL, Liu AY, Castillo-Mancilla JR, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/aac.01710-17.
Castillo-Mancilla JR, Morrow M, Coyle RP, et al. Tenofovir diphosphate in dried blood spots is strongly associated with viral suppression in individuals with HIV infection. Clin Infect Dis. 2018. https://doi.org/10.1093/cid/ciy708.
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
Gandhi M, Glidden DV, Liu A, et al. Strong correlation between concentrations of tenofovir (TFV) emtricitabine (FTC) in hair and TFV diphosphate and FTC triphosphate in dried blood spots in the iPrEx open label extension: implications for pre-exposure prophylaxis adherence monitoring. J Infect Dis. 2015;212(9):1402–6.
Eaton EF, Tamhane A, Davy-Mendez T, et al. Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure. AIDS (London, England). 2018;32(3):347–55.
Breslow NE. Statistics in epidemiology: the case–control study. J Am Stat Assoc. 1996;91(433):14–28.
Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004;5(2):74–9.
Motulsky H. Intuitive biostatistics: a nonmathematical guide to statistical thinking. New York: Oxford University Press; 2014.
The Lancet H. U = U taking off in 2017. Lancet HIV. 2017;4(11):e475.
Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830–9.
Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–81.
Mills JC, Pence BW, Todd JV, et al. Cumulative burden of depression and all-cause mortality in women living with HIV. Clin Infect Dis. 2018;67(10):1575–81.
Kumar S, Rao PS, Earla R, Kumar A. Drug–drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert Opin Drug Metab Toxicol. 2015;11(3):343–55.
Midde NM, Rahman MA, Rathi C, et al. Effect of ethanol on the metabolic characteristics of HIV-1 integrase inhibitor elvitegravir and elvitegravir/cobicistat with CYP3A: an analysis using a newly developed LC-MS/MS method. PLoS ONE. 2016;11(2):e0149225.
Decloedt EH, Lesosky M, Maartens G, Joska JA. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial. AIDS Res Therapy. 2017;14(1):6.
Dalessandro M, Conti CM, Gambi F, et al. Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. J Clin Psychopharmacol. 2007;27(1):58–61.
Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47(3):384–90.
Kumar V, Encinosa W. Effects of antidepressant treatment on antiretroviral regimen adherence among depressed HIV-infected patients. Psychiatric Q. 2009;80(3):131–41.
Yun LW, Maravi M, Kobayashi JS, Barton PL, Davidson AJ. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38(4):432–8.
Kalichman SC, Grebler T, Amaral CM, et al. Viral suppression and antiretroviral medication adherence among alcohol using HIV-positive adults. Int J Behav Med. 2014;21(5):811–20.
Socias ME, Milloy MJ. Substance use and adherence to antiretroviral therapy: what is known and what is unknown. Curr Infect Dis Rep. 2018;20(9):36.
MacBrayne CE, Marks KM, Fierer DS, et al. Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. J Antimicrob Chemother. 2018;73(8):2112–9.
Chuah FLH, Haldane VE, Cervero-Liceras F, et al. Interventions and approaches to integrating HIV and mental health services: a systematic review. Health Policy Plan. 2017;32(Suppl_4):iv27–47.
DeLorenze GN, Satre DD, Quesenberry CP, Tsai AL, Weisner CM. Mortality after diagnosis of psychiatric disorders and co-occurring substance use disorders among HIV-infected patients. AIDS Patient Care STDs. 2010;24(11):705–12.
Acknowledgements
We would like to thank all study participants and the personnel at the Colorado Antiviral Pharmacology Laboratory for their invaluable assistance and support of this study. We would also like to thank the director of the UCH-HIV program (Steven Johnson, MD), the medical assistants (Nancy Olague, Brittany Limon, Ariel Cates, Maureen Sullivan and Missy Sorrell) and the nursing staff (Joslyn Axinn, Jackie Deavers, and Ann Czyz) at the UCH-IDGP for their invaluable contributions and support of this study.
Funding
Funding was provided through the National Institutes of Health (K23 AI104315 to J.C.M.; R01 AI122298 to P.L.A.; R56 MH117131-01 to C.D.S.). C.D.S. has received Ryan White funding. P.L.A., J.J.K., and L.R.B. have received research funding from Gilead Sciences, paid to their institution. J.J.K. has also received research funding from Janssen Therapeutics and ViiV Healthcare, paid to their institution.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No conflicts of interest were reported from all remaining authors. Each author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts of interest that the editors consider relevant to the content of the manuscript have been disclosed.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Colorado Multiple Institutional Review Board (COMIRB; protocol 13-2104) and was registered at ClinicalTrials.gov (NCT02012621).
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Coyle, R.P., Schneck, C.D., Morrow, M. et al. Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy. AIDS Behav 23, 3493–3502 (2019). https://doi.org/10.1007/s10461-019-02441-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-019-02441-8